(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) has submitted a Clinical Trial Authorization application to The Medicines and Healthcare Products Regulatory Agency in the United Kingdom to begin a phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
Alnylam Pharmaceuticals plans to begin the phase 1 study in patients with early-onset Alzheimer's disease in early 2022, upon obtaining MHRA approval, and expects to report initial human data at or around year-end 2022.
ALN-APP, the first-ever RNAi therapeutic targeting CNS diseases, is being advanced in partnership with Regeneron as part of Alnylam Pharma's 2019 agreement.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
